Phase I/II Trial of Immunotherapy with Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early trial report

Current strategies to improve clinical outcomes in KRAS-mutant non-small cell lung cancer (NSCLC) patients include MEK inhibitor and PD-1 / PD-L1 immune checkpoint blockade (ICB) combinations. Experience from melanoma suggests that anti-CTLA-4 and anti-PD-1 / PD-L1 combinations improve outcomes, but...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Lung Cancer
Main Authors: Gaudreau, Pierre-Olivier, Lee, J. Jack, Heymach, John V., Gibbons, Don L.
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656492/
https://ncbi.nlm.nih.gov/pubmed/32299768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2020.02.019
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker